|
|
Post by sla55 on Jun 3, 2022 9:06:13 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-host-product-theater-and-booth-american-diabetesWESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and expanding efforts within the diabetes community at the American Diabetes Association’s 82nd Scientific Sessions, June 3-7 in New Orleans. “MannKind is committed to providing products that address unmet needs for patients living with diabetes,” said Alejandro Galindo, Executive Vice President, Endocrine Business Unit for MannKind Corporation. “This effort is demonstrated by our growing portfolio of products, including Afrezza® and V-Go®, that change the way diabetes is managed.” When the exhibit hall opens at ADA, MannKind will host a booth (Booth #1019) to share information about its expanding diabetes products, host meetings with health care professionals (HCPs). MannKind will also publish an abstract on “Augmenting Clinical Trial Data within Silico Evidence to Evaluate Initial Conversion Dose Changes for Technosphere® Insulin (TI).” The abstract will be published in category 12-E Clinical Therapeutics/New Technology – Insulins. MannKind will present a Product Theater event (product theater #3) on Saturday, June 4 at 4:30 p.m. (ET) discussing “Ultra Rapid-Acting Inhaled Insulin for Diabetes Management.” Dr. Kevin Kaiserman, Vice President, Medical Affairs & Safety, Endocrine Business Unit for MannKind Corporation, will be joined by Dr. Steven Edelman and Dr. Jeremy Pettus of Taking Control Of Your Diabetes (TCOYD) to speak during the program.
|
|
|
|
Post by sayhey24 on Jun 3, 2022 10:14:15 GMT -5
Lets hope Mike got these "Thought Leaders" (Dr. Steven Edelman and Dr. Jeremy Pettus) a new bullhorn for some live "Seeing is Believing" demos at the theater. I hope they are also sponsoring a Happy Hour with some more live demos.
MannKind will present a Product Theater event (product theater #3) on Saturday, June 4 at 4:30 p.m. (ET) discussing “Ultra Rapid-Acting Inhaled Insulin for Diabetes Management.” Dr. Kevin Kaiserman, Vice President, Medical Affairs & Safety, Endocrine Business Unit for MannKind Corporation, will be joined by Dr. Steven Edelman and Dr. Jeremy Pettus of Taking Control Of Your Diabetes (TCOYD) to speak during the program.
|
|
|
|
Post by akemp3000 on Jun 3, 2022 10:54:36 GMT -5
Lets hope Mike got these "Thought Leaders" (Dr. Steven Edelman and Dr. Jeremy Pettus) a new bullhorn for some live "Seeing is Believing" demos at the theater. I hope they are also sponsoring a Happy Hour with some more live demos. MannKind will present a Product Theater event (product theater #3) on Saturday, June 4 at 4:30 p.m. (ET) discussing “Ultra Rapid-Acting Inhaled Insulin for Diabetes Management.” Dr. Kevin Kaiserman, Vice President, Medical Affairs & Safety, Endocrine Business Unit for MannKind Corporation, will be joined by Dr. Steven Edelman and Dr. Jeremy Pettus of Taking Control Of Your Diabetes (TCOYD) to speak during the program. I agree. I'm not especially fond of a 4:30 time slot as visitors get tired and have diminishing attendance late in the day but associating it with a happy hour and more could be excellent. |
|
|
|
Post by veritasfiliatemporis on Jun 3, 2022 11:09:51 GMT -5
At 10 still sleeping, at 12 waiting the lunch, 14 digesting, 16 thinking about the happy hour event but at 1630 all present at Mannkind presentation before the happy hour that starts at 1730..
|
|
|
|
Post by factspls88 on Jun 3, 2022 12:07:30 GMT -5
I'll admit I haven't kept up to speed entirely on everything going on with Mannkind but I do check the board fairly often, especially when the stock moves significantly. Today I am noticing that Mannkind is presenting a product theater event referring to Afrezza as "ULTRA-RAPID ACTING." Also, a video was posted today where Dr. Steven Edelman, a long time Afrezza proponent, referred to Afrezza as Ultra-Rapid Acting. Did I miss something??? Have they received approval for using the term "Ultra"? This was something that I recall Al Mann fought for when alive to indicate superiority over other mealtime insulin but he was unsuccessful. It has been a long slog for me so excuse me if I missed this.
|
|
|
|
Post by tarheelblue004 on Jun 3, 2022 12:17:01 GMT -5
They received approval for using the term "Ultra" a while ago. The big change is that MannKind has re-oriented their business around the Ultra Rapid mealtime insulin market, a smaller but faster-growing segment of the overall mealtime insulin market. Mike talked about this on one of the last calls - everything from the sales KPIs to what we're seeing in the marketing is due to going all-in on this segment.
|
|
|
|
Post by factspls88 on Jun 3, 2022 12:20:29 GMT -5
They received approval for using the term "Ultra" a while ago. The big change is that MannKind has re-oriented their business around the Ultra Rapid mealtime insulin market, a smaller but faster-growing segment of the overall mealtime insulin market. Mike talked about this on one of the last calls - everything from the sales KPIs to what we're seeing in the marketing is due to going all-in on this segment. Thanks! |
|
|
|
Post by sayhey24 on Jun 5, 2022 8:33:03 GMT -5
They received approval for using the term "Ultra" a while ago. The big change is that MannKind has re-oriented their business around the Ultra Rapid mealtime insulin market, a smaller but faster-growing segment of the overall mealtime insulin market. Mike talked about this on one of the last calls - everything from the sales KPIs to what we're seeing in the marketing is due to going all-in on this segment. Got approval from who? I don't remember seeing it in the ADA SoC where the categories are listed. I always thought it was being used as a marketing term which has not been challenged with the FDA. In the ADA SoC I still don't know the new class name which would be good; powdered monomer insulin? |
|
|
|
Post by sayhey24 on Jun 5, 2022 8:34:08 GMT -5
Does anyone have a video from the Big show yesterday? Did "Buzz" Harris send anything out?
|
|
|
|
Post by sportsrancho on Jun 5, 2022 9:56:14 GMT -5
I can’t find anything, would be nice if somebody could:-)
|
|
|
|
Post by mango on Jun 5, 2022 10:58:36 GMT -5
If you will notice, Afrezza is the ONLY insulin that claims the term Ultra within its official website. All the RAAs use the term fast or rapid. Reason being, Afrezza actually has the scientific data to back up the claim of ultra rapid acting—no other insulin does. Afrezza is the standard for ultra rapid acting.
If you’ll also notice, other diabetes companies will use the term ultra during PRs and paid published articles, but on the official product websites they do NOT use that term. Likely, they know they can’t legally and ethically do so. For them, it’s a fraudulent marketing scheme, for MannKind its just the reality of Afrezza.
|
|
|
|
Post by cretin11 on Jun 5, 2022 12:20:31 GMT -5
If you will notice, Afrezza is the ONLY insulin that claims the term Ultra within its official website. All the RAAs use the term fast or rapid. Reason being, Afrezza actually has the scientific data to back up the claim of ultra rapid acting—no other insulin does. Afrezza is the standard for ultra rapid acting. If you’ll also notice, other diabetes companies will use the term ultra during PRs and paid published articles, but on the official product websites they do NOT use that term. Likely, they know they can’t legally and ethically do so. For them, it’s a fraudulent marketing scheme, for MannKind its just the reality of Afrezza. What is the definition of ultra in this context, i.e. what is required for a company to use the term ultra on its product website rather than just in PRs? |
|
|
|
Post by mango on Jun 5, 2022 13:26:42 GMT -5
If you will notice, Afrezza is the ONLY insulin that claims the term Ultra within its official website. All the RAAs use the term fast or rapid. Reason being, Afrezza actually has the scientific data to back up the claim of ultra rapid acting—no other insulin does. Afrezza is the standard for ultra rapid acting. If you’ll also notice, other diabetes companies will use the term ultra during PRs and paid published articles, but on the official product websites they do NOT use that term. Likely, they know they can’t legally and ethically do so. For them, it’s a fraudulent marketing scheme, for MannKind its just the reality of Afrezza. What is the definition of ultra in this context, i.e. what is required for a company to use the term ultra on its product website rather than just in PRs? MannKind uses ultra in the context of mimicking physiologic insulin. Is it the best term to use? In my opinion, no, but this is the trend that ADA and BP prefers. With Afrezza, insulin is released into the bloodstream in less than 1 minute and begins lowering blood glucose within 12 minutes—regardless of dose, this timeframe is consistent—something not seen with RAAs. Return to baseline in ~90min with 4units and ~180 with 12units. Incredible. |
|
|
|
Post by agedhippie on Jun 5, 2022 16:21:32 GMT -5
Usually the term ultra rapid/fast insulin is used for Fiasp and Lyumjev. Needless to say it's important that Afrezza to keep on top of this. The term itself is relatively meaningless as it isn't an FDA class, but it is important for marketing as it becomes a self-defined group. Mannkind needs to ensure that it doesn't get drowned out in the group.
|
|
|
|
Post by sayhey24 on Jun 5, 2022 18:37:03 GMT -5
Aged - I think you mean ADA class but until the ADA defines the class its more of a marketing thing.
If I remember correctly when Fiasp tried to get the Ultra class the ADA did not know what to do about afrezza so they did nothing rather than stir the hornets nest with Kendall. IMO while afrezza is faster in and out than Fiasp and Lyumjec its proper class should probably be "powdered monomer insulin". Right now the ADA refers to it as "inhaled insulin" which would include Exubera and any other "inhaled insulin" which may happen to show up.
|
|
